RT vs TR-Cetuximab . Essai BONNER 213 patients Etude prospective randomisée
Cetuximab/RT > RT alone for
- median duration of locoregional control (24,4 mois vs 14,9 mois) (hazard ratio for locoregianl progression or death, 0,68 ; P=0,005)
- median duration of overall survival (44 mois vs 29,3 mois) (hazard ration for death, 0,74; P=0,003)
- progression free survival (hazard ration for disease progression or death , 0,70; P=0,006)
​
With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups.
James A. Bonner
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
N Engl J Med 2006;354:567-78